DigestRedComo funciona
Red
/
Empresas
Se
No verificado

Seaport Therapeutics

Sobre qué escribimos

BiotecnologíaEventosFarmacéuticaMedicina - VariosSalud

20 Comunicados de prensa

Ver todos los comunicados de prensa
05/01/2026
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Eventos
Finanzas
Seaport Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
Fuente
Seaport Therapeutics
Editor
Business Wire
1.00
0
08/12/2025
Eventos
Medicina alternativa
Salud
Medicina - Varios
Seaport Therapeutics Presents Data Further Validating Glyph™ Platform’s Ability to Enhance Oral Bioavailability and Expand Therapeutic Reach
Fuente
Seaport Therapeutics
Editor
Business Wire
1.00
0
04/12/2025
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Eventos
Web y redes sociales
Seaport Therapeutics to Present at 2025 RBC Capital Markets Healthcare Private Company Conference
Fuente
Seaport Therapeutics
Editor
Business Wire
1.00
0
04/11/2025
Eventos
Web y redes sociales
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Seaport Therapeutics to Present at Stifel 2025 Healthcare Conference
Fuente
Seaport Therapeutics
Editor
Business Wire
1.00
0
18/09/2025
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Web y redes sociales
Eventos
Seaport Therapeutics to Participate in Upcoming Investor Conferences
Fuente
Seaport Therapeutics
Editor
Business Wire
1.00
0
11/09/2025
Ciencia
Biotecnología
Farmacéutica
Salud
Psiquiatría
Medicina - Varios
Industria
Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo™ (SPT-320) in Healthy Volunteers
Fuente
Seaport Therapeutics
Editor
Business Wire
1.00
0
17/07/2025
Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress
Fuente
Seaport Therapeutics
Editor
Business Wire
1.00
0
24/04/2025
Eventos
Industria
Biotecnología
Psiquiatría
Salud
Farmacéutica
Medicina - Varios
Seaport Therapeutics Presents New Preclinical Data on SPT-320 (Glyph Agomelatine) at the Society of Biological Psychiatry (SOBP) Annual Meeting
Fuente
Seaport Therapeutics
Editor
Business Wire
1.00
0
31/03/2025
Web y redes sociales
Eventos
Biotecnología
Psiquiatría
Salud
Farmacéutica
Seaport Therapeutics to Participate in Upcoming Investor Conferences in April
Fuente
Seaport Therapeutics
Editor
Business Wire
1.00
0
11/03/2025
Mercado laboral
Psiquiatría
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair
Fuente
Seaport Therapeutics
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0